Trek Therapeutics in the News
October, 2017 - Pharmafocus Article: Securing the Cold Chain with New Solutions
August 21, 2020 - Milano Finanza Article: Ambrosus signs Agreement with Trek for Blockchain Protocol
July, 2017 - HCV Patient Access: Trek Therapeutics Takes the Road Less Traveled
May, 2017 - Article: “Dancing to the Same Tune?” in Trends in Patient Centricity
April 20, 2020 - Eyeforpharma Interview with Ann Kwong, Part I
April 20, 2020 - Eyeforpharma Interview with Ann Kwong, Part II
Mar 2, 2020 - Article: “A Marriage Made in Heaven” at eyeforpharma.com
Dec 14, 2020 - STAT Interview with Trek Therapeutics CEO Ann Kwong
Nov 3, 2016 - Washington Post feature article
Press Releases
Feb 13, 2020 -Trek Therapeutics Announces Oral Presentation of Faldaprevir, TD-6450 and Ribavirin Ph2a Trial Results at the Asian Pacific Association for the Study of the Liver on February 18, 2020 in Shanghai
[PDF]
Sep 15, 2020 - Interim Results from Trek Therapeutics’ Phase 2 Study Show Triple Combination Therapy Achieves 100% SVR4 in Genotype 4 HCV Patients
[PDF]
Aug 17, 2020 - Medivir Licenses Rights to MIV-802 to Trek Therapeutics
Jul 26, 2020 -Trek Therapeutics Acquires Two Antiviral Inhibitors From Vertex Pharmaceuticals
[PDF]
Jun 21, 2020 -Trek Therapeutics Initiates Phase 2a Study of Faldaprevir and TD-6450, With and Without Ribavirin, in Patients with HCV GT 1b
[PDF]
Oct 27, 2020 - Theravance Biopharma and Trek Therapeutics Announce Initiation of Phase 2a Trial of TD-6450, an NS5A Inhibitor to Treat Hepatitis C
[PDF]
Presentations/Publications by Trek-affiliated Members
Antiviral Research, 149 (2018) 34-40
Merimepodib, an IMPDH inhibitor, suppresses replication of Zika virus and other emerging viral pathogens
HEP DART 2015, December 6-10, Wailea, USA
Price and Affordability of Hepatitis C Drugs: How Did We Get Into This Mess? (Cami Graham, MD, MPH)
Eliminating HCV: Why Highly Effective Drugs Are Not Enough (Ann Kwong, PhD)